1. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987;28:1358–1362
2. Sharkey RM, Blumenthal RD, Hansen HJ, Goldenberg DM. Biological considerations for radioimmunotherapy. Cancer Res 1990;50(Suppl 3):964s–969s
3. DeNardo GL, DeNardo SJ. Overview of obstacles and opportunities for radioimmunotherapy of cancer. In: Goldenberg DM, editor. Cancer therapy with radiolabeled antibodies. Boca Raton, FL: CRC Press; 1995. pp 141–154
4. White CA. Radioimmunotherapy in non-Hodgkin’s lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin). J Exp Ther Oncol 2004;4:305–316
5. Goodwin DA, Meares CF. Advances in pretargeting biotechnology. Biotechnol Adv 2001;19:435–450